Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

Recruiting

Phase 3

TezepelumabOpen-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

Sponsor:

AstraZeneca

Code:

NCT06473779

Conditions

Severe Asthma

Eligibility Criteria

Sex: All

Age: 12 - 70+

Healthy Volunteers: Not accepted

Interventions

Tezepelumab

Budesonide/formoterol

Albuterol/budesonide (AIRSUPRA®)

Mannitol

Salbutamol

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-12. This information was provided to ClinicalTrials.gov by AstraZeneca on 2025-12-12.